Efficacy of injectable maropitant (Cerenia™) in a randomized clinical trial for prevention and treatment of cisplatin‐induced emesis in dogs presented as veterinary patients
Authors:
- 12 February 2007
- journal article
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 5 (1) , 38-46
Abstract
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of cisplatin therapy. Maropitant (Cerenia™), a novel neurokinin-1 receptor antagonist, was evaluated for prevention and treatment of cisplatin-induced emesis in tumour-bearing dogs. Dogs (n= 122) were randomly allocated to three treatment groups: T01, placebo before and after cisplatin; T02, placebo before and maropitant after cisplatin; or T03, maropitant before and placebo after cisplatin. Maropitant treatment (T02) following a cisplatin-induced-emetic event resulted in significantly fewer subsequent emetic events (P= 0.0005) than in placebo-treated dogs (T01). In placebo-treated (T01) dogs, 56.4% were withdrawn from the study because of treatment failure compared with 5.3% in group T02. When maropitant was administered prior to cisplatin treatment (T03) in a prevention regime, 94.9% did not vomit compared with only 4.9% of placebo-treated dogs, and significantly fewer emetic events (P < 0.0001) were observed in those dogs that did vomit. In summary, maropitant was safe and highly effective in reducing or completely preventing cisplatin-induced emesis.Keywords
This publication has 15 references indexed in Scilit:
- American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006Journal of Clinical Oncology, 2006
- Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatmentEuropean Journal of Cancer, 2005
- Veterinary Co‐operative Oncology GroupVeterinary and Comparative Oncology, 2004
- THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGSDrug Metabolism and Disposition, 2004
- Functional relevance of antiemetic controlEuropean Journal of Cancer, 2003
- The broad‐spectrum anti‐emetic activity of the novel non‐peptide tachykinin NK1 receptor antagonist GR203040British Journal of Pharmacology, 1995
- The anti‐emetic effects of CP‐99,994 in the ferret and the dog: role of the NK1 receptorBritish Journal of Pharmacology, 1995
- Plasma Levels of Peptide YY Correlate with Cisplatin-induced Emesis in DogsJournal of Pharmacy and Pharmacology, 1994
- Increase in serotonin levels in the dog ileum and blood by cisplatin as measured by microdialysisNeuropharmacology, 1993
- Vagal Afferent Fibers and Peripheral 5-HT3 Receptors Mediate Cisplatin-Induced Emesis in DogsJapanese Journal of Pharmacology, 1992